{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:35:53Z","timestamp":1791513353424,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"DOI":"10.7759\/cureus.85377","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:48:12Z","timestamp":1749102492000},"source":"Crossref","is-referenced-by-count":15,"title":["A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease"],"prefix":"10.7759","author":[{"given":"Umesh C","family":"Chundu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree Ram","family":"Thiriveedhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetanya","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya Sai","family":"Mupparaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Otinashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elene","family":"Gelishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Alzheimer\u2019s Disease","author":"Seeley WW","year":"2020","unstructured":"Seeley WW, Miller BL. Alzheimer\u2019s Disease. Harrison's Principles of Internal Medicine. Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (ed): McGraw-Hill Education, 2020."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000369101","article-title":"Amyloid-beta: a crucial factor in Alzheimer's disease","volume":"24","author":"Sadigh-Eteghad S","year":"2015","unstructured":"Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J. Amyloid-beta: a crucial factor in Alzheimer's disease. Med Princ Pract. 2015, 24:1-10. 10.1159\/000369101","journal-title":"Med Princ Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2012.06.002","article-title":"Viewpoint: crosstalks between neurofibrillary tangles and amyloid plaque formation","volume":"12","author":"Luan K","year":"2013","unstructured":"Luan K, Rosales JL, Lee KY. Viewpoint: crosstalks between neurofibrillary tangles and amyloid plaque formation. Ageing Res Rev. 2013, 12:174-81. 10.1016\/j.arr.2012.06.002","journal-title":"Ageing Res Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer\u00a0disease","volume":"15","author":"Panza F","year":"2019","unstructured":"Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer\u00a0disease. Nat Rev Neurol. 2019, 15:73-88. 10.1038\/s41582-018-0116-6","journal-title":"Nat Rev Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein S","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al.. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022, 9:197-210. 10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson CJ","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, et al.. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021, 13:80. 10.1186\/s13195-021-00813-8","journal-title":"Alzheimers Res Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck CH","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al.. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023, 388:9-21. 10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun MA","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al.. Donanemab in early Alzheimer's disease. N Engl J Med. 2021, 384:1691-704. 10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"Prisma2020: An R package and shiny app for producing Prisma 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. Prisma2020: An R package and shiny app for producing Prisma 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022, 18:e1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref10","unstructured":"RoB 2. a revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias. (2025). Accessed: April 2, 2025: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials.."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway S","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, et al.. Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022, 79:13-21. 10.1001\/jamaneurol.2021.4161","journal-title":"JAMA Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0193-y","article-title":"Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies","volume":"8","author":"Ivanoiu A","year":"2016","unstructured":"Ivanoiu A, Pariente J, Booth K, et al.. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Alzheimers Res Ther. 2016, 8:24. 10.1186\/s13195-016-0193-y","journal-title":"Alzheimers Res Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160216","article-title":"Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer's disease patients","volume":"57","author":"Ketter N","year":"2017","unstructured":"Ketter N, Brashear HR, Bogert J, et al.. Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer's disease patients. J Alzheimers Dis. 2017, 57:557-73. 10.3233\/JAD-160216","journal-title":"J Alzheimers Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-171157","article-title":"Long-term follow up of patients with mild-to-moderate Alzheimer's disease treated with bapineuzumab in a phase III, open-label, extension study","volume":"64","author":"Salloway SP","year":"2018","unstructured":"Salloway SP, Sperling R, Fox NC, et al.. Long-term follow up of patients with mild-to-moderate Alzheimer's disease treated with bapineuzumab in a phase III, open-label, extension study. J Alzheimers Dis. 2018, 64:689-707. 10.3233\/JAD-171157","journal-title":"J Alzheimers Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe R","year":"2016","unstructured":"Vandenberghe R, Rinne JO, Boada M, et al.. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016, 8:18. 10.1186\/s13195-016-0189-7","journal-title":"Alzheimers Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160369","article-title":"A phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer's disease","volume":"54","author":"Brody M","year":"2016","unstructured":"Brody M, Liu E, Di J, et al.. A phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer's disease. J Alzheimers Dis. 2016, 54:1509-19. 10.3233\/JAD-160369","journal-title":"J Alzheimers Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki S","year":"2022","unstructured":"Ostrowitzki S, Bittner T, Sink KM, et al.. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022, 79:1113-21. 10.1001\/jamaneurol.2022.2909","journal-title":"JAMA Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims JR","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al.. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. J Am Med Assoc. 2023, 330:512-27. 10.1001\/jama.2023.13239","journal-title":"J Am Med Assoc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease","volume":"113","author":"Gueorguieva I","year":"2023","unstructured":"Gueorguieva I, Willis BA, Chua L, et al.. Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease. Clin Pharmacol Ther. 2023, 113:1258-67. 10.1002\/cpt.2875","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman RJ","year":"2023","unstructured":"Bateman RJ, Smith J, Donohue MC, et al.. Two phase 3 trials of gantenerumab in early Alzheimer's disease. N Engl J Med. 2023, 389:1862-76. 10.1056\/NEJMoa2304430","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade E","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, et al.. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022, 14:191. 10.1186\/s13195-022-01124-2","journal-title":"Alzheimers Res Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig LS","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, et al.. Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med. 2018, 378:321-30. 10.1056\/NEJMoa1705971","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody RS","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, et al.. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014, 370:311-21. 10.1056\/NEJMoa1312889","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng E","year":"2022","unstructured":"Teng E, Manser PT, Pickthorn K, et al.. Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2022, 79:758-67. 10.1001\/jamaneurol.2022.1375","journal-title":"JAMA Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208061","article-title":"Assessment of efficacy and safety of Zagotenemab: results from PERISCOPE-ALZ, a Phase 2 study in early symptomatic Alzheimer disease","volume":"102","author":"Fleisher AS","year":"2024","unstructured":"Fleisher AS, Munsie LM, Perahia DG, et al.. Assessment of efficacy and safety of Zagotenemab: results from PERISCOPE-ALZ, a Phase 2 study in early symptomatic Alzheimer disease. Neurology. 2024, 102:e208061. 10.1212\/WNL.0000000000208061","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/368193-a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-monoclonal-antibodies-in-alzheimers-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:48:13Z","timestamp":1749102493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/368193-a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-monoclonal-antibodies-in-alzheimers-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.85377","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}